Brice Jabo1, Ann C Lin2, Mayada A Aljehani1, Liang Ji1, John W Morgan1,3, Matthew J Selleck2, Hahns Y Kim4, Sharon S Lum5. 1. Loma Linda University School of Public Health, Loma Linda, CA, USA. 2. Division of Surgical Oncology, Department of Surgery, Loma Linda University School of Medicine, Loma Linda, CA, USA. 3. Surveillance Epidemiology and End Results (SEER) Cancer Registry, Cancer Registry of Greater California and California Cancer Registry, Sacramento, Loma Linda, CA, USA. 4. Department of Plastic Surgery, Loma Linda University School of Medicine, Loma Linda, CA, USA. 5. Division of Surgical Oncology, Department of Surgery, Loma Linda University School of Medicine, Loma Linda, CA, USA. slum@llu.edu.
Abstract
BACKGROUND: Delays in surgery and adjuvant treatment for breast cancer are associated with decreased survival. However, the time between diagnosis and surgery is rising, partly attributed to the added complexity of immediate breast reconstruction (IBR). We sought to investigate time to treatment and survival outcomes in breast cancer patients undergoing IBR. METHODS: We performed a retrospective review of 2004-2014 California Cancer Registry data for stage 0-III breast cancer patients undergoing mastectomy. Time to surgery, adjuvant systemic therapy and radiation therapy, propensity score, and covariate-adjusted overall mortality hazard ratios (HRs) were assessed by IBR status. RESULTS: Of 56,782 patients, 13,738 (24.2%) underwent IBR, with a median follow-up of 68.8 months. Median time between diagnosis and surgery was increased for patients undergoing IBR compared with those without {49 days (interquartile range [IQR] 34-73) vs. 35 days (IQR 21-56), p < 0.001}. IBR did not affect the interval from surgery to adjuvant chemotherapy or radiation, but prolonged time to endocrine therapy by 5 days (p = 0.014). Significantly lower survival was observed when time to surgery exceeded 120 days (vs. 0-30 days; HR 1.14 [1.02-1.28], p = 0.023), and improved survival with IBR (vs. without; HR 0.67 [0.61-0.74], p < 0.001). The benefit associated with reconstruction persisted for all age groups except age 80 + years, while surgical delay > 120 days demonstrated significantly lower survival in women < 60 years of age. CONCLUSIONS: While IBR delays time to definitive surgery, its use did not substantially affect time to adjuvant treatment or survival outcomes. Further research is ongoing to mitigate the effects of potential selection bias in favor of IBR.
BACKGROUND: Delays in surgery and adjuvant treatment for breast cancer are associated with decreased survival. However, the time between diagnosis and surgery is rising, partly attributed to the added complexity of immediate breast reconstruction (IBR). We sought to investigate time to treatment and survival outcomes in breast cancerpatients undergoing IBR. METHODS: We performed a retrospective review of 2004-2014 California Cancer Registry data for stage 0-III breast cancerpatients undergoing mastectomy. Time to surgery, adjuvant systemic therapy and radiation therapy, propensity score, and covariate-adjusted overall mortality hazard ratios (HRs) were assessed by IBR status. RESULTS: Of 56,782 patients, 13,738 (24.2%) underwent IBR, with a median follow-up of 68.8 months. Median time between diagnosis and surgery was increased for patients undergoing IBR compared with those without {49 days (interquartile range [IQR] 34-73) vs. 35 days (IQR 21-56), p < 0.001}. IBR did not affect the interval from surgery to adjuvant chemotherapy or radiation, but prolonged time to endocrine therapy by 5 days (p = 0.014). Significantly lower survival was observed when time to surgery exceeded 120 days (vs. 0-30 days; HR 1.14 [1.02-1.28], p = 0.023), and improved survival with IBR (vs. without; HR 0.67 [0.61-0.74], p < 0.001). The benefit associated with reconstruction persisted for all age groups except age 80 + years, while surgical delay > 120 days demonstrated significantly lower survival in women < 60 years of age. CONCLUSIONS: While IBR delays time to definitive surgery, its use did not substantially affect time to adjuvant treatment or survival outcomes. Further research is ongoing to mitigate the effects of potential selection bias in favor of IBR.
Authors: Ronnie J Zipkin; Andrew Schaefer; Changzhen Wang; Andrew P Loehrer; Nirav S Kapadia; Gabriel A Brooks; Tracy Onega; Fahui Wang; Alistair J O'Malley; Erika L Moen Journal: Ann Surg Oncol Date: 2022-05-24 Impact factor: 4.339
Authors: Seung Ho Baek; Soon June Bae; Chang Ik Yoon; So Eun Park; Chi Hwan Cha; Sung Gwe Ahn; Young Seok Kim; Tai Suk Roh; Joon Jeong Journal: J Breast Cancer Date: 2019-01-22 Impact factor: 3.588
Authors: Neal Bhutiani; Adam C Hicks; Bin Huang; Quan Chen; Thomas C Tucker; Kelly M McMasters; Nicolás Ajkay Journal: J Surg Oncol Date: 2020-03-29 Impact factor: 2.885
Authors: E Heeg; J X Harmeling; B E Becherer; P J Marang-van de Mheen; M T F D Vrancken Peeters; M A M Mureau Journal: Br J Surg Date: 2019-08-06 Impact factor: 6.939